These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 15214781

  • 41. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 42. A new class of glycogen phosphorylase inhibitors.
    Lu Z, Bohn J, Bergeron R, Deng Q, Ellsworth KP, Geissler WM, Harris G, McCann PE, McKeever B, Myers RW, Saperstein R, Willoughby CA, Yao J, Chapman K.
    Bioorg Med Chem Lett; 2003 Nov 17; 13(22):4125-8. PubMed ID: 14592521
    [Abstract] [Full Text] [Related]

  • 43. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
    Tsirkone VG, Tsoukala E, Lamprakis C, Manta S, Hayes JM, Skamnaki VT, Drakou C, Zographos SE, Komiotis D, Leonidas DD.
    Bioorg Med Chem; 2010 May 15; 18(10):3413-25. PubMed ID: 20430629
    [Abstract] [Full Text] [Related]

  • 44. New inhibitors of glycogen phosphorylase as potential antidiabetic agents.
    Somsák L, Czifrák K, Tóth M, Bokor E, Chrysina ED, Alexacou KM, Hayes JM, Tiraidis C, Lazoura E, Leonidas DD, Zographos SE, Oikonomakos NG.
    Curr Med Chem; 2008 May 15; 15(28):2933-83. PubMed ID: 19075645
    [Abstract] [Full Text] [Related]

  • 45. Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents.
    Singh N, Pandey SK, Anand N, Dwivedi R, Singh S, Sinha SK, Chaturvedi V, Jaiswal N, Srivastava AK, Shah P, Siddiqui MI, Tripathi RP.
    Bioorg Med Chem Lett; 2011 Aug 01; 21(15):4404-8. PubMed ID: 21737274
    [Abstract] [Full Text] [Related]

  • 46. CoMFA and docking studies on glycogen phosphorylase a inhibitors as antidiabetic agents.
    Prathipati P, Pandey G, Saxena AK.
    J Chem Inf Model; 2005 Aug 01; 45(1):136-45. PubMed ID: 15667139
    [Abstract] [Full Text] [Related]

  • 47. The structure of brain glycogen phosphorylase-from allosteric regulation mechanisms to clinical perspectives.
    Mathieu C, Dupret JM, Rodrigues Lima F.
    FEBS J; 2017 Feb 01; 284(4):546-554. PubMed ID: 27782369
    [Abstract] [Full Text] [Related]

  • 48. Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.
    Fosgerau K, Westergaard N, Quistorff B, Grunnet N, Kristiansen M, Lundgren K.
    Arch Biochem Biophys; 2000 Aug 15; 380(2):274-84. PubMed ID: 10933882
    [Abstract] [Full Text] [Related]

  • 49. Discovery and evaluation of novel benzazepinone derivatives as glycogen phosphorylase inhibitors with potent activity.
    Wang Y, Yan Z, Guo Y, Zhang L.
    Future Med Chem; 2021 May 15; 13(10):897-909. PubMed ID: 33906369
    [Abstract] [Full Text] [Related]

  • 50. Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.
    Whittamore PR, Addie MS, Bennett SN, Birch AM, Butters M, Godfrey L, Kenny PW, Morley AD, Murray PM, Oikonomakos NG, Otterbein LR, Pannifer AD, Parker JS, Readman K, Siedlecki PS, Schofield P, Stocker A, Taylor MJ, Townsend LA, Whalley DP, Whitehouse J.
    Bioorg Med Chem Lett; 2006 Nov 01; 16(21):5567-71. PubMed ID: 16945526
    [Abstract] [Full Text] [Related]

  • 51. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity.
    Navarrete-Vazquez G, Paoli P, León-Rivera I, Villalobos-Molina R, Medina-Franco JL, Ortiz-Andrade R, Estrada-Soto S, Camici G, Diaz-Coutiño D, Gallardo-Ortiz I, Martinez-Mayorga K, Moreno-Díaz H.
    Bioorg Med Chem; 2009 May 01; 17(9):3332-41. PubMed ID: 19362487
    [Abstract] [Full Text] [Related]

  • 52. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

  • 53. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149.
    Lerín C, Montell E, Nolasco T, García-Rocha M, Guinovart JJ, Gómez-Foix AM.
    Biochem J; 2004 Mar 15; 378(Pt 3):1073-7. PubMed ID: 14651477
    [Abstract] [Full Text] [Related]

  • 54. Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives.
    Karis ND, Loughlin WA, Jenkins ID, Healy PC.
    Bioorg Med Chem; 2009 Jul 01; 17(13):4724-33. PubMed ID: 19443226
    [Abstract] [Full Text] [Related]

  • 55. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
    Oikonomakos NG.
    Curr Protein Pept Sci; 2002 Dec 01; 3(6):561-86. PubMed ID: 12470212
    [Abstract] [Full Text] [Related]

  • 56. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 57. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX, Wang YD, Yan ZW, Zhang LY.
    Bioorg Med Chem Lett; 2020 Jul 15; 30(14):127117. PubMed ID: 32527535
    [Abstract] [Full Text] [Related]

  • 58. Pentacyclic triterpenes. Part 5: synthesis and SAR study of corosolic acid derivatives as inhibitors of glycogen phosphorylases.
    Wen X, Xia J, Cheng K, Zhang L, Zhang P, Liu J, Zhang L, Ni P, Sun H.
    Bioorg Med Chem Lett; 2007 Nov 01; 17(21):5777-82. PubMed ID: 17869102
    [Abstract] [Full Text] [Related]

  • 59. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.
    Oikonomakos NG, Kosmopoulou MN, Chrysina ED, Leonidas DD, Kostas ID, Wendt KU, Klabunde T, Defossa E.
    Protein Sci; 2005 Jul 01; 14(7):1760-71. PubMed ID: 15987904
    [Abstract] [Full Text] [Related]

  • 60. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).
    Donnier-Maréchal M, Vidal S.
    Expert Opin Ther Pat; 2016 Jul 01; 26(2):199-212. PubMed ID: 26666989
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.